Intelligenome
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • HOME
  • Technology
    • CRISPR-Based Diagnostics
    • CRISPR-TB Benchtop Assay
    • CRISPR-TB Point of Care
    • Landmark Publications
  • Applications
    • Tuberculosis (TB)
    • NTM
    • MAC
    • Oncology
  • Resources
    • Partnerships
    • News Releases
    • Events
    • Blog
  • About
    • Corporation
    • Executive Team
  • Careers
  • Contact
  • More
    • HOME
    • Technology
      • CRISPR-Based Diagnostics
      • CRISPR-TB Benchtop Assay
      • CRISPR-TB Point of Care
      • Landmark Publications
    • Applications
      • Tuberculosis (TB)
      • NTM
      • MAC
      • Oncology
    • Resources
      • Partnerships
      • News Releases
      • Events
      • Blog
    • About
      • Corporation
      • Executive Team
    • Careers
    • Contact
Intelligenome

Signed in as:

filler@godaddy.com

  • HOME
  • Technology
    • CRISPR-Based Diagnostics
    • CRISPR-TB Benchtop Assay
    • CRISPR-TB Point of Care
    • Landmark Publications
  • Applications
    • Tuberculosis (TB)
    • NTM
    • MAC
    • Oncology
  • Resources
    • Partnerships
    • News Releases
    • Events
    • Blog
  • About
    • Corporation
    • Executive Team
  • Careers
  • Contact

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

CRISPR-TB Point-of-Care Blood Assay

Rapid, Accessible, and Ultra-Sensitive TB Detection at the Point of Care

IntelliGenome introduces its first point-of-care (POC) molecular diagnostic solution, the CRISPR-TB POC Blood Assay*, designed to bring ultra-sensitive tuberculosis (TB) detection closer to patients. This single-test solution detects Mycobacterium tuberculosis (Mtb) DNA from nucleic acids in plasma or serum, enabling the accurate, rapid, and affordable diagnosis of both pulmonary (PTB) and extra-pulmonary tuberculosis (EPTB) across all patient groups. 


Self-Contained & Simplified Testing


The CRISPR-TB POC Blood Assay is a self-contained diagnostic system with minimal sample collection and processing requirements, making it ideal for decentralized testing in clinics, rural areas, and resource-limited settings.

Lab in Tube (LIT): Next-Generation POC TB Testing

Building on its pioneering CRISPR diagnostic technology, IntelliGenome has developed Lab in Tube (LIT)*, an advanced point-of-care molecular diagnostic platform designed for portability, ease of use, and accessibility.

Key Features of Lab in Tube (LIT)

  •  All-in-One Testing Device – Integrates all necessary reagents to isolate and detect Mtb cfDNA in a single, compact device.
  • Portable & Scalable – Designed for use in resource-constrained regions, making TB testing accessible for all patient groups, regardless of age or health conditions.
  •  Fluorescent Signal Detection – Works with a portable, reusable fluorescent signal reader for accurate real-time analysis.

How It Works: Three-Stage Testing System

  1. DNA Amplification Module: Contains high-fidelity DNA polymerase, PCR buffer with stabilization proteins, dNTPs, and primer pairs targeting TB IS-6110 sequences for nucleic acid amplification.
  2. CRISPR Detection Module: Incorporates a Cas enzyme reaction with a specially formulated reaction buffer, fluorescent probes, gRNA, and disposable paper strips for CRISPR-based target detection.
  3. TB Identification Module: Features paper strips for precise TB-IS6110 detection, a DNA sequence unique to Mycobacterium tuberculosis. These strips provide clear visual confirmation of test results.

Flexible & Cost-Effective Deployment

  • Disposable Test Kits – LIT components are single-use and designed for rapid, on-site TB testing.
  • Portable Fluorescent Readers– Sold separately for long-term, cost-efficient use across multiple tests.

 With the CRISPR-TB POC Blood Assay and LIT, IntelliGenome is revolutionizing TB diagnostics—offering a portable, accurate, and accessible solution for global TB eradication efforts.

Contact Us

*The CRISPR-TB Point-of-Care (POC) Blood Assay and Lab in Tube (LIT) are currently under development and have not yet received regulatory approval for diagnostic or clinical use.

Copyright © 2025 IntelliGenome - All Rights Reserved.

8955 Interchange Dr, Houston, TX 77054

  • CRISPR-Based Diagnostics
  • CRISPR-TB Benchtop Assay
  • CRISPR-TB Point of Care

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept